Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Merck's Keytruda Loss In Liver Cancer Could Be Gain For Rivals

Feb 20 2019

• By Emily Hayes

liver

Related Content

Keeping Track: FDA's Review Actions Carry On During Shutdown

Jan 20 2019

<em>Avastin</em> Loses Its Breast Cancer Claim; FDA’s Hamburg Opts For Withdrawal Over Restrictions

Nov 21 2011

Keytruda Clears Low Hurdle In Stage III Melanoma

Jan 09 2018

Keeping Track Of Approvals: Cancer, Cancer, And A Two-Week Cancer Review

Nov 19 2018

Merck's Keytruda Lead Widens Over Competing Checkpoint Inhibitors

Feb 02 2019

Keytruda/Inlyta Data Stoke Competition In Kidney Cancer

Feb 12 2019

First In 10 Years, But Lenvima's First-Line Liver Label Could Be Challenged Soon

Aug 17 2018

Pipeline Watch: Phase III Starts For BL-8040, Trigriluzole, MIN-101

Dec 22 2017

Lartruvo Phase III Fail Rocks Lilly Oncology Plans

Jan 21 2019

Related Companies

Merck & Co., Inc.

Pfizer Inc.

Roche Holding AG

Eli Lilly and Company

Bristol Myers Squibb Company

Bayer AG

Exelixis, Inc.

Eisai Co., Ltd.

Additional Topics

Clinical Trials Research & Development ImmunoOncology BioPharmaceutical

More from Clinical Trials

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window